Forward compatibility is your bridge from eCTD v3 to v4. We have covered the "why" and the "how" in our previous posts; now, it is time to map out the "when." Transitioning to eCTD v4 is not an overnight task; it requires a strategic rollout and a proactive approach to testing your processes in a collaborative environment.
This final part of our series provides a plan for building that bridge, focusing on the pioneering efforts currently underway at the European Medicines Agency (EMA).
Building Your Internal Roadmap
To transition smoothly and maintain the integrity of your medicinal product information, your organization should focus on four key strategic areas:
-
Inventory and Application Assessment:
Identify which products in your portfolio are a priority for the eCTD v4 transition. By categorizing your products early, you can prioritize applications where forward compatibility delivers the highest immediate value.
-
Active Vendor Partnership:
Rather than managing technical XML structures alone, talk to your solution provider. Our intention is to act as a partner to navigate you through the technical complexities, ensuring your infrastructure is ready for the shift without manual intervention.
-
Business Process Readiness:
Update your internal workflows to ensure every member of your regulatory department understands the transition. This isn't just about software; it’s about ensuring your team is prepared for a new way of managing data quality.
-
Expert-Led Guidance:
Instead of getting lost in the technical nuances of "Context of Use" or validation errors, elude the heavy lifting to the experts. Professional training and expert support ensure a "first-time-right" submission by focusing on the business logic rather than just the code.
The EMA eCTD v4 Pilot: A Unique Opportunity
The European Medicines Agency (EMA) is the first authority worldwide to actively implement forward compatibility. This represents a critical window for companies to:
-
Test Readiness in Real-Time:
Observe exactly how the v3-to-v4 link performs within the EMA’s review environment.
-
Collaborate with Regulators:
Understand how assessors navigate the consolidated lifecycle and gain direct insight into their expectations.
-
Refine Strategy Before the Mandate:
Use pilot findings to optimize your business processes well before the mandatory transition in 2026.
Phase III: Mastering the Transition
Phase III of the EMA eCTD v4 Pilot is particularly significant as it covers complex scenarios, such as transitioning during an initial MAA. Participating in the pilot is about more than technical testing; it is about setting the standard for digital innovation in the life sciences industry through a close partnership between industry and regulators.
The Path Forward
The move from eCTD v3 to eCTD v4 is a milestone toward a more data-driven and efficient regulatory landscape. By mastering forward compatibility with the right partners, you ensure your past data continues to support your future successes.
At EXTEDO, we are proud to support the EMA and our global partners in this transition. Backed by the cormeo ecosystem - including Rote Liste, Docuvera, and medicines.ie - our solutions support tomorrow's success already today.
Are you ready to bridge the gap? Contact us today to discuss your eCTD v4 transition strategy. Together, we will find your way to regulatory excellence!
Forward compatibility is your bridge from eCTD v3 to eCTD v4. Read our previous posts on the “why” and the “how” to get the full picture:
Forward Compatibility: The Bridge to eCTD v4
Forward Compatibility in eCTD v4 – How to Carry Your Current eCTD v3 Application History Into the Future
